Global ETD Search

251	Messenger RNA : a tool for studying neuropeptide expression in locust CNS King, Sarah Louise January 1997 (has links) No description available. 572.8 Insulin; Insect nervous system
252	Glutamate receptor subunits as a determinant of selective vulnerability in neurodegenerative disease Williams, Timothy Laurence January 2000 (has links) No description available. 612 Central nervous system; Ionotropic
253	Phenotypic and genetic analysis of the hindshaker mutation King, Helen Anne January 1997 (has links) No description available. 636.089 Myelinogenesis; Central nervous system
254	Phenotypic analysis of rumpshaker mutation on two different genetic backgrounds Al-Saktawi, Khalid A. January 2002 (has links) No description available. 573 Murine central nervous system
255	Cellular and molecular studies on olfactory bulb ensheathing cells Franceschini, Isabelle A. January 1997 (has links) No description available. 610 Nervous system; Glial cells
256	Putative neurotransmitters in selected helminth parasites : cellular and subcellular localisation Brownlee, David Joseph Acheson January 1993 (has links) No description available. 571.4 Neuropeptides; Central nervous system
257	Intracellular responses to histamine and adenosine in rat brain-derived glian cells Peakman, Marie-Claire January 1994 (has links) No description available. 615.1 Neuroglia; Central nervous system
258	An investigation into the role of Fas ligand as a potential immunomodulatory molecule for CNS gene therapy Regardsoe, Emma Louise January 2000 (has links) No description available. 572.8 Adenoviral; Nervous system; Central
259	Improving clinical trial design in neurodegenerative disorders McGhee, David J. M. January 2014 (has links) This thesis aimed to improve the methodology of disease-modification clinical trials in neurodegenerative disorders, with particular reference to Parkinson's disease (PD) and Alzheimer's disease. A systematic review was undertaken to determine what biomarkers for disease progression in PD exist, and whether any have sufficient evidence to be used in clinical trials. Included studies (n=183) were generally of poor quality, being cross-sectional with small numbers of participants, applying excessive inclusion/exclusion criteria, having flawed methodologies and applying simplistic statistical analyses. Insufficient evidence was, therefore, found to recommend the use of any disease progression biomarker in PD clinical trials. A subsequent review in Alzheimer's disease (n=59) demonstrated that these issues were not unique to PD. A 'roadmap' was, therefore, developed to improve future disease progression biomarker studies. The sensitivity to change of a range of PD clinical outcome measures was analysed using data from a follow-up study of an incident cohort of patients with parkinsonism. The MMSE, total UPDRS and PDQ-39 summary index were the most sensitive to change of the continuous outcome measures examined. Amongst binary outcome measures, a new 'dead or dependent' outcome measure was most sensitive to change, and was shown to be a feasible outcome measure for future PD RCTs. Finally, a systematic review was undertaken to examine the validity of differing clinical trial designs used in Alzheimer's disease and PD to demonstrate disease-modification. A variety of design strategies, including wash-in and wash-out analyses, delayed-start designs and long-term follow-up studies, have been used but have methodological limitations. No evidence was found of novel clinical trial designs having been used previously or planned for use in the future. Final recommendations are made that future disease-modification trials should be long-term follow-up studies involving newly diagnosed patients. 'Dead or 'dependent' is highlighted as an efficacious measure to use in such trials. 616.8 Nervous system ; Clinical trials
260	A clinico-pathological and animal experimental study of multiple system atrophy Wenning, Gregor Karl January 1996 (has links) No description available. 610 Nervous system; Degenerative disease

Search results